Antifungal Drugs Market overview
Antifungal drugs are used to cure fungal infections, which occur due to, unclean, unhygienic and damp environment. Fungal infections are caused by microscopic organisms invading epithelial tissue. Systemic fungal infections are usually caused by the indigestion or inhalation of fungus spores and cause fungal pneumonia and opportunistic fungus causes diseases such as candidaisis, meningitis, mucormycosis and some others. Though most of the fungal infections and diseases are non-lethal, they are very uncomfortable to live with and their common occurrence is responsible for the emerging antifungal drugs market. Antifungal drugs work using various mechanisms such as by inhibiting cell wall formation, cell membrane disruption and cell division.
The major factors driving the market are increasing awareness of fungal infections with the growing incidence of antifungal infections all over the world, increasing government and corporate funding in the industry. Further, the development of public private partnership in the pharmaceutical industry and the rising popularity of over-the-counter antifungal drugs for dermal infections is responsible for the growing antifungal drugs market size. Also, the rise in population with weak immune system due to cancer chemotherapy or acquired immunodeficiency syndrome, in whom the occurrence of fungal infections is much more than average, will drive the market. High penetration of conventional drugs used for the treatment of fungal infections is restraining the market growth. The key challenges faced by the market are cost of drugs and their effectiveness in treatments.
Antifungal Drugs Market Forecast Report (2018-2023)
Antifungal Drugs Market was worth $13.06 billion in 2018 and estimated to be growing at a CAGR of 3.68%, to reach $15.65 billion by 2023. The market is expected to grow enormously in the next few years, with the growing global population.
Antifungal Drugs Market Segmentation
(fluconazole, itraconazole, ketoconazole, posaconazole, and voriconazole) are systemically acting, Echinocandins (anidulafungin,
The antifungal drugs market is segmented based on drug type into Echinocandins, Azoles, Polyenes, Allylamines, and Other Drugs. Also, the market is segmented by type of therapeutic indications into Aspergillosis, Dermatophytosis, Candidiasis and Other therapeutic indications. And the market is also segmented by applications into Powders, Ointments, Drugs, Pastes. While Azolesand micafungin) are lipopeptides derived from natural fungal fermentation products and Polyenes (amphotericin B deoxycholate and liposomal amphotericin B Corifungin) are systemically acting and disrupt eukaryotic cellular membranes. Azoles antifungal drug market is the largest segment of the market followed by echinocandins antifungal drug market.caspofungin
On the basis of geography, the global market is analyzed under regions namely North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. North America and Europe together contribute to a major share of the global antifungal drugs market, while the market in Asia-Pacific is the fastest growing followed by Latin America.
Major Key Players
Some of the major companies dominating the market
[CI1]Discuss the major companies that are operating in the market. Identify the top companies.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Drug Type
5.1.1 Echinocandins
5.1.2 Azoles
5.1.3 Polyenes
5.1.4 Allylamines
5.1.5 Others
5.2 By Therapeutic Indications
5.2.1 Aspergillosis
5.2.2 Dermatophytosis
5.2.3 Candidiasis
5.2.4 Others
5.3 By Application
5.3.1 Powders
5.3.2 Ointments
5.3.5 Drugs
5.3.4 Pastes
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Alternaria
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Pfizer
8.3 Novartis
8.4 Sanofi-Aventis
8.5 Merck & Co.
8.6 Asperqillus
8.7 Kramer Laboratories
8.8 Bayer Healthcare
8.9 Enzon Pharmaceuticals
8.10 Glaxosmithkline Gilead
8.11 Abbott Laboratories
9. Competitive Landscape
9.1 Market share analysis
